Aspect Biosystems, a Vancouver startup pursuing a diabetes cell therapy, received $79 million from the Canadian government. The award is framed as a way to preserve the company’s Canadian development and manufacturing footprint as it advances next-generation diabetes therapeutics. The grant matters because cell therapy scale-up and supply chain decisions can quickly shift based on site economics and ecosystem capacity. Large public funding can influence whether a company retains critical operational stages in its home country. The report did not specify the exact program use of funds, but the headline impact is clear: government capital is underwriting clinical and manufacturing readiness for a diabetes cell-therapy effort tied to Canada.